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1 Oral Adjuvant Therapy for Colorectal Cancer: Recent Developments and Future Targets
2
3 Abstract:
4 Colorectal cancer (CRC) is considered the third most frequent malignant neoplasm occurring in 
5 both men and women worldwide.  Most approaches that have been used to fight and treat this 
6 type of malignancy are either invasive or non-selective. Non-invasive therapy using oral route 
7 can increase patient compliance and reduce treatment costs. Innovative measures such as use of 
8 nanotechnology and theranostic systems have been initiated in the oral therapy, which has been 
9 proven to be greatly advantageous in decreasing side effects, improving detection and diagnoses. 
10 This manuscript investigates recent innovative and novel therapeutic approaches through oral 
11 route and potential targets in the treatment of CRC. 
12 Keywords: Colorectal cancer, targeted therapy, nanotechnology, oral chemotherapy, 
13 immunotherapy, monoclonal antibodies, theranostic systems
14 1. Introduction
15 Cells in our body receive different information signals and process them, these signals may allow 
16 them to either grow, divide, differentiate or undergo apoptosis. However, when these signals 
17 reaching the cells are not followed and get out of control, then these cells become known as 
18 cancer cells. Cancer cells are cells that keep on growing, replicating and spreading although they 
19 are located near non-stimulated cells [1].
20 There are more than one hundred different types of cancer which are unique from one another by 
21 their behavior and response to treatment [2]. Cancer incidents and mortality rates are keep on 
22 increasing globally. It was estimated that in 2018 the new cancer incidents will increase up to 
23 18.1 million in addition to that the death rates are predicted to reach up to 9.6 million [3]. Among 
24 different types of cancer, CRC is ranked as a third common cancer occurring in both genders 
25 worldwide. In addition to that, it is second cancer leading to mortality after lung cancer in both 
26 men and women according to the 2018 cancer statistics [3]. According to recent statistics 
27 conducted in 2019 for the ten leading cancer types for the estimated new cancer cases and deaths 
28 by sex in the United States, CRC ranked 3rd in terms of deaths and incidents after prostate and 
29 lung cancer in males, and breast and lung cancer in females. The statistics show that there are 
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30 about 78,500 new estimated cases and 27,640 estimated deaths in males. On the other hand, there 
31 are 67,100 new estimated cases and 23,380 estimated deaths in females [4].
32 CRC is caused by the abnormal division of cells taking place in rectum as well as in colon 
33 region. The earliest phase of CRC starts with the appearance of clusters of enlarged crypts that 
34 proliferate abnormally, known as polyps. The majority of CRCs develop from abnormal polyps 
35 that later become malignant due to the infiltration to the submucosa [5]. CRCs have many 
36 symptoms associated with it, the main symptoms include rectal bleeding, diarrhea or constipation 
37 which are better known as changing bowel habits, and other symptoms include weight loss, 
38 abdominal discomfort and anemia [6]. There are number of risk factors associated with CRC. 
39 The CRC is more likely in people who had inflammatory bowel diseases and family history of 
40 CRC since the factors disposing CRC such as Lynch Syndrome is caused by a germline mutation 
41 in MMR gene [7]. Approximately half of the families that had Lynch Syndrome carrygermline 
42 mutation in MMR genes. Diseases and gut flora disturbance are also predisposing factors to CRC 
43 as the disturbance in the microbiota is able to induce diseases such as IBD or cancers. The 
44 following bacteria were found to impact cancer development such as Escherichia coli 
45 Helicobacter pylori, Enterococcus faecalis, Clostridium septicum, Streptococcus 
46 bovis,Fusobacterium spp., and Bacteroides fragilis [8]. Sedentary lifestyle, smoking, age, 
47 increased BMI, poor diet that lacks vegetables and fruits while being high in red meat were also 
48 major risk factors associated with the disease [9,10].
49 Luckily, nowadays there are various approaches to treatment options available for CRC such as 
50 surgery, chemotherapy, radiotherapy and targeted therapies. However, these treatment options 
51 differ depending on the stage of CRC (Table 1). The most common treatment for CRC is usually 
52 surgery or chemotherapy, most of the patients of the metastatic phase or CRC are candidates for 
53 systemic chemotherapy to increase the quality of life and decrease the symptoms [11]. Currently 
54 available adjuvant therapies are depicted in Figure 1.
55 Intravenous (IV) 5-Fluorouracil (5-FU) is the main drug of choice used for CRC. Moreover, new 
56 advances in the field of oncology have been developed [12] and recently scientists have 
57 introduced new treatment methods such as laparoscopic surgery, resection of metastatic disease, 
58 neoadjuvant and palliative chemotherapy. Nevertheless, long-term survival and cure rates were 
59 found to give only minimal results [13].
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60 Although IV route is most commonly used, patients were seen to prefer oral chemotherapy in 
61 comparison to IV chemotherapy that was observed in the study which was comparing patient 
62 preference between oral UFT versus IV 5-FU and leucovorin [14].  The patient choice was 
63 influenced by compliance and drug toxicity. That being said, patients try to avoid traditional 
64 invasive therapy and that was a factor that spiked the scientists’ interest to develop new drug 
65 delivery systems that can be given to the patient orally as an oral cancer treatment is having 
66 many advantages such as patient compliance and acceptance as well as cost saving [15].
67 Innovative measures have been initiated with the oral therapy as there were previous limitations 
68 with the bioavailability primarily because of cytochrome P450 (CYP) activity and drug 
69 transporters, such as P-glycoprotein (P-gp) in gut wall and liver [16]. The use specific, low-
70 toxicity inhibitors of CYP3A4, (P-gp), and other drug metabolizing enzymes such as 
71 dihydropyrimidine dehydrogenase was initiated as a solution to this problem that lead to the 
72 success of the oral chemotherapy formulations [17]. Other notable innovations that helped oral 
73 cancer therapy was the use of nanotechnology and advanced targeted drug delivery systems [18] 
74 that were either encapsulating chemotherapeutic drugs [19] or being coated with cell surface 
75 specific antigens such as monoclonal antibodies [20]. Theranostic nanomedicine is a recent 
76 technology to fight against cancers in addition to providing diagnoses and scanning applications 
77 as an all in one treatment. This system includes nanoshells, plasmonicnanobubbles, quantum dots 
78 etc. Such new advances in nanoimaging and nanotherapy open doors to the development of 
79 effective cancer treatment [21].
80 The purpose of this review is to provide the reader with complete up-to-date information related 
81 to oral adjuvant therapy options that are available for CRC. This review further examines 
82 innovative measures such as use of nanotechnology and theranostic systems along with an 
83 overview of potential targets in the treatment of CRC.
84 Oral Route of Administration
85 Currently, the adjuvant therapy of colorectal cancer mostly requires IV administration, 
86 necessitates regular visits to clinics. IV route of administration further leads to discomfort, 
87 infection and chances of extravasation. Oral route of administration offers significant advantages 
88 like flexibility in the design of dosage form, ease of manufacturing with least sterility constraints, 
89 patient convenience, self-administration, cost-effectiveness. However, oral bioavailability of 
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90 many anticancer drugs are low and highly variable, low solubility and low permeability, 
91 instability, and metabolism by intestinal and hepatic enzymes. Therefore, only few oral therapies 
92 are available in market and are presented in Table 2.
93 After oral administration, there are two main pathways through which drug act on colon cancer 
94 as depicted in Figure 2. The first pathway follow absorption of drugs into systemic circulation, 
95 while second pathway allows local targeting to colon site. Several strategies for enhancing oral 
96 bioavailability are being pursued including the development of pro-drugs, the co-administration 
97 of inhibitors of enzyme and transporter activity, and various formulation approaches, such as 
98 excipient enhancement, and polymeric- and lipid-based nanocarriers that deliver the medicine 
99 through the lymphatic system. Local delivery at colonic site such as prodrugs, covalent linkage 
100 of a drug with a carrier, pressure dependent systems, pH-sensitive systems, timed released 
101 systems, microbially triggered systems, bioadhesive systems, osmotic controlled drug delivery 
102 systems can also be utilized to deliver high drug payload to the colonic site. The benefit of this 
103 approach can be demonstrated by the fact if 5-FU delivered specifically to the colon, its 
104 distribution and thus side effects to other organs and tissues can be minimized. In addition, 5-FU 
105 get converted to active metabolite 5-fluoro-2′-deoxyuridine by the colon tumor, the benefits of 
106 the 5-FU therapy can be maximized [22]. Therefore, this approach for local colon delivery for 
107 colon cancer is well investigated and very well reviewed [23] and hence are not discussed 
108 further.
109 Capecitabine
110 An oral fluoropyrimidine drug that has been developed, it acts as a prodrug of 5-FU and is 
111 absorbed intact from the intestine which later undergoes a series of conversions until it yields 
112 Doxifluridine that gets converted to 5-FU. Capecitabine showed better results than 5-FU as it 
113 was showed to elevate the levels of 5-FU up to three times in the tumor as compared to healthy 
114 tissue after its administration to cancer patients [24].
115 A randomized phase III study was conducted by Hoff PM et al. to compare capecitabine with 
116 bolus 5FU/LV treatment regimen. It was found the tumor response rate to be significantly higher 
117 in the capecitabine group (24.8%) than in the 5-FU/LV group (15.5%; P =.005). In addition to 
118 that capecitabine produced significantly lower incidence of diarrhea, stomatitis, nausea, and 
119 alopecia, as well as grade 3/4 stomatitis and grade 3/4 neutropenia thus significantly less 
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120 neutropenic fever/sepsis. However, only grade 3 hand-foot syndrome and grade 3/4 
121 hyperbilirubinemia toxicities were more frequent in capecitabine than with 5-FU/LV treatment 
122 [25].
123 Oral Irinotecan (CPT-11)
124 Irinotecan is a topoisomerase inhibitor [26], that is usually given via IV route to treat cancer, 
125 recent studies and clinical trials are testing irinitecan when given via oral route. One of these 
126 studies showed a phase I dose-escalation trial of irinotecan being administered orally by mixing 
127 CPT-11 IV solution with cran-grape juice to measure its maximum tolerated dose and its dose-
128 limiting toxicities in cancer patients with solid tumors. The results have shown Grade 4 delayed 
129 diarrhea was the dose-limiting toxicities at the 80 mg/m2/d dosage in patients younger than 65 
130 years of age and at the 66 mg/m2/d dosage in patients 65 or older. As neutropenia was found to 
131 be the major toxicity or oral irinotecan and one patient with previously treated CRC and liver 
132 metastases succeeded in getting a partial response. The findings have led to the conclusion that 
133 dose-limiting toxicities of diarrhea are similar to that observed with IV administration of CPT-
134 11, as well as the need for further clinical development [27].
135 Another phase I oral irinotecan study was made by giving it daily for 14 days every 3 weeks in 
136 45 patients with solid tumors to study its pharmacokinetic profile. This time the drug was given 
137 via oral route in a powder-filled capsule at doses ranging from 7.5 to 40 mg/m2 per day. The 
138 dose-limiting toxicities found were grade 3 nausea, grade 3/4 vomiting and diarrhea as well as 
139 one occurrence of grade 3 asthenia, as for the maximum tolerated dose it was found at 30 mg/m2 
140 per day, and two partial responses were documented [28].
141 Oxaliplatin
142 New studies that are aiming to transfer chemotherapeutic agents to oral treatments have 
143 developed Oxaliplatin as an oral formulation to be tested against CRC. This preparation method 
144 included the encapsulation of the chemotherapeutic agent in pH-sensitive alginate microsphere 
145 that has been coated with the mucoadhesive chitosan. The aim behind such formulation was to 
146 protect the drug and make sure that it gets released after passing the acidic GIT media thus 
147 targeting the intestines. This formulation was studied on an orthotopic mouse model of CRC and 
148 was able to reduce the tumor in addition to the mortality[29]. In another study, scientists test the 
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149 synergistic activity of combining the oral formulation of TAS-102 (Lonsurf) along with 
150 intravenous Oxaliplatin against colorectal and gastric cancer cells using a mouse model. TAS-
151 102 (Lonsurf) is a new antitumor agent that consists of trifluridine (FTD) along with tipiracil 
152 hydrochloride, a thymidine phosphorylase inhibitor approved to be used in the treatment of CRC 
153 that is either unresectable advanced or recurrent. Results have shown that the tumor growth-
154 inhibitory activity and RTV5 in the animal mouse model given TAS-102 with oxaliplatin were 
155 showing significantly better results than those given monotherapy. Overall the results indicated 
156 that such a synergistic combination give promising results for either CRC or gastric cancer and 
157 can be used against tumors that have not received chemotherapy before as well as those that have 
158 been treated with 5-FU and showed 5-FU resistance [30]. Based on the results of these two 
159 studies, we suggest studying the synergistic effect of oral TAS-102 and oral oxaliplatin on CRC.
160 Nanotechnology and advanced drug delivery systems
161 CRC treatment effectiveness is getting limited recently due to the chemotherapy resistance [31]. 
162 This resistance is either intrinsic or acquired and it lowers the effectiveness of the 
163 chemotherapeutic drugs leading to poor patient response, its mechanism is mainly by reducing 
164 drug accumulation and elevating drug export in addition to changing drug targets, and repairing 
165 the DNA damaged by chemotherapy. Other factors include stroma and cancer stem cells [32]. 
166 Thus this slow growth in the cancer treatments calls for the need for new therapeutic approaches 
167 such as nanosystems or nanotechnology to solve drug delivery problems[33]. Nanoparticles were 
168 showing great potential for therapeutic molecule protection, transport and loading with various 
169 physiological properties [34–36] as well are targeting and having multiple functions [37,38]. 
170 Nanocarrier based drugs which are also known as nanomedicines have shown great benefits in 
171 fighting cancer stem cells (CSC) that were having significant effects on tumor progression and 
172 drug resistance as well as cancer metastasis. These nanomedicines were able to deliver an 
173 adequate amount of the drug to the tumor-targeted cells especially the CSC's niches and this was 
174 not seen in other drug delivery systems since it was considered as a limitation in the conventional 
175 treatment methods [39]. Nanomedicines have shown great therapeutic effectiveness against 
176 pump-mediated drug resistance as well as reducing the harmful effects on normal stem cells due 
177 to its selectivity [40]. The in-vivo mechanisim at which such nano-particles work falls into a 
178 four-step process which includes: the transport through blood circulation to tumor regions via 
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179 blood vessels; transport across vasculature walls into surrounding tumor tissues; penetrate 
180 through the interstitial space to target cells; and cellular uptake by endocytosis and intracellular 
181 delivery. Cellular uptake by endocytosis was found to be achieved through five main different 
182 mechanisms, including phagocytosis, clathrin-mediated endocytosis, caveolin-mediated 
183 endocytosis, clathrin/caveolae-independent endocytosis and micropinocytosis [41].
184 The newly developed nanomedicine treatments of diseases such as intestinal cancer are showing 
185 promising opportunities in clinical trials [42]. A recent study used a squaline based nanoparticle 
186 filled with cisplatin (SQ-CDDP NP) [43]. The effect of this new formulation was measured by 
187 using a mouse model having intestinal cancer. The results have shown a difference of 10 folds 
188 greater with the new nano-formulation in comparison to un-complexed cisplatin, further 
189 investigation showed that the nano-formulation SQ-CDDP NP stimulated the reactive oxygen 
190 species as well as heavy metal and stress-induced gene expressions and finally apoptosis. It is 
191 also demonstrated that ferulic acid from plant sources can be chemically modified to form 
192 poly(ferulic acid) (PFA) to prepare nanoparticles. Both PFA blank and loaded with paclitaxel 
193 showed colon tumor inhibition suggesting PFA itself has an anticancer effect in vivo [44] and 
194 thus not only enhance drug delivery, but also provide additional anticancer benefits to the 
195 patients. Same group also prepared doxorubicin loaded PFA nanoparticles that where shown to 
196 released drug continuously under slightly acidic conditions in vitro mimicking the conditions of 
197 acidic tumor microenvironments suggested effective drug delivery at tumor site. These 
198 nanoparticles showed enhanced permeability and retention at tumor site in vivo while reducing 
199 the toxicity of free doxorubicin and improving its safety [45]. 
200 Nanoemulsion systems have been also used in the treatment of CRC, a recent study used a 
201 cisplatin third generation analogue known as oxaplatin that is used as first-line therapy in 
202 combination with 5-FU in the treatment of CRC. Since both drugs have a low bioavailability due 
203 to bad membrane permeability a new invention was needed to increase their efficacy. An ion 
204 pairing complex was created between oxaplatin and a deoxycholic acid derivative to increase 
205 permeability followed by the preparation of water-in-oil-in-water nano-emulsions including 
206 oxaplatin/deoxycholic acid and 5-FU to increase the drug absorption when taken orally.The 
207 study also tested the membrane permeability by using Caco-2 cell monolayer and an artificial 
208 intestinal membrane. Then by using the mouse animal model bioavailability testing and CRC cell 
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209 growth inhibition was conducted after administering the formulation orally and the results have 
210 shown greater in vivo permeability and a significant increase in oral absorption and 
211 bioavailability, as well as better tumor growth inhibition. Thus all these findings gave a better 
212 understanding of the importance of using nanomedicine and its development in treating cancer as 
213 well as using it in oral combination therapies for CRC[46].
214 Another advanced targeted drug delivery system that has been introduced to be used against 
215 CRC is the use of liposomes when combined with a chemotherapeutic drug. In a recent 
216 study[47], two anti-cancer drugs have been used in the treatment of CRC the first one being 
217 Apatinibmesylate, a new and selective VEGFR-2 inhibitor that can be used to treat a variety of 
218 tumors and the second one being docetaxel (Taxotere), a traditional anticancer drug that is a 
219 semisynthetic taxoid in solid tumors. The drug delivery systems used were a liposome and 
220 methoxypoly(ethylene glycol)-poly(ε-caprolactone) (MPEG-PCL) to deliver apatinib (Lipo-Apa) 
221 and docetaxel, correspondingly. The Co-administration of the two systems showed synergistic 
222 effects on stopping the cell proliferation and inducing cell programmed death of CT26 cells in 
223 vitro. Moreover, when the treatment was given to the animal model a significant improvement 
224 was shown in the anti-tumor activity in a subcutaneous xenograft model in addition to the 
225 abdominal metastasis model of CRC. thus leading to the conclusion that these two formulations 
226 have the potential to be used clinically in CRC therapy[47].In another study, liposomes were 
227 conjugated with folic acid enclosing Oxaliplatin a monoclonal antibody and entrapped in alginate 
228 beads coated with Eudragit-S-100 to be administered orally to the animal mouse model have 
229 CRC tumors[48]. The study showed positive results with the ability of these beads to be used as 
230 a potential carrier in CRC.
231 Furthermore, newer advanced targeting techniques were introduced such as formulating folic 
232 acid conjugated liposomes containing Oxiplatin and entrapping them inside aliginate beads that 
233 were coated with Eudragit-S-100 to achieve effective drug delivery to CRC site [48].  Oral 
234 aliginate microcapsules have also been formulated  to successfully deliver curcumin-loaded 
235 micelles to the CRC and promote the concept of chemotherapy at home [49].
236 Scientists have also succeeded in the development of a targeted large intestinal oral nanoparticle 
237 vaccine that is consisting of pH-dependent microparticles to induce colorectal immunity. This 
238 study was done on a mouse animal model in order to see the efficacy of such a vaccine in the 
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239 protection against rectal or vaginal viral changes to the mucosa. The study has also stated the 
240 potential application of this new delivery technology to be used in different forms of vaccines 
241 such as DNA, recombinant proteins, peptides as well as others. Furthermore, it suggested a new 
242 approach to formulate vaccines fighting against mucosal malignancies such as colorectal as well 
243 as cervical cancer [50].
244 Immunotherapy
245 Immunotherapy treatments function by overcoming or relieving tumour-induced 
246 immunosuppression, thereby enabling immune-mediated tumour clearance[51]. Recently cancer 
247 immunotherapy has become a validated clinical treatment for various types of cancers. This kind 
248 of treatment has many approaches to the cancer treatment such as the use of cancer vaccines, 
249 adoptive transfer of ex vivo activated T and natural killer cells, oncolytic viruses, and the use of 
250 antibodies or recombinant proteins that may co-stimulate cells or cause blockage to the immune 
251 checkpoint pathways [52].
252 Angiogenesis has always been a concern with tumor formation and metastasis, thus 
253 antiangiogenic treatments are available these days. The use of monoclonal antibodies (mAbs) is 
254 promising treatment option and receiving remarkable clinical success for lymphomas and solid 
255 tumors [53].
256 A recently developed small-molecule inhibitor of vascular endothelial growth factor receptor-2 
257 (VEGFR-2) which is better known as Apatinib has shown to possess oral bioavailability when 
258 treating various cancers yet it’s still being studied under clinical trials [54]. A recent case report 
259 that was published on the use of Apatinib as a third line therapy given to two Chinese patients 
260 having metastatic CRC displayed promising benefits after the drug treatment the chance of 
261 prolonged survival of mCRC patients along with good safety and tolerability profile. The first 
262 patient who was a 52-year-old female achieved progression-free survival period of four months 
263 and an overall survival of eleven months however she did not continue the treatment due to 
264 abdominal distension and loss of appetite. On the other, hand the second patient who was a 59-
265 year-old man, achieved progression-free survival period of more than ten months later on due to 
266 PD is shown on frequent CT scans the drug administration was stopped. This case report 
267 suggested further investigation on the drug to be given as a single drug or in combinations, as 
268 well as it raised the question of the use of this drug in other ethnic groups due to regional 
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269 differences. Finally report recommended further research on the mechanisms of drug resistance, 
270 alternative triggers of angiogenesis, and the potential predictive biomarkers that aid in patient 
271 selection [55].
272 Regorafenib is another orally administered monoclonal antibody that is the first small-molecule 
273 multi-kinase inhibitor used for metastatic CRC. Regorafenib has undergone a phase 3 trial and 
274 showed an overall survival benefit in comparison to the placebo that shows its potential to be 
275 used with patients who didn't respond to standard treatments[56].
276 Theranostic Systems and new developments for CRC treatment 
277 Nowadays researchers are looking for methods to monitor and treat the human body by 
278 noninvasive means. Nanotechnology was the gate to develop a noninvasive detection method 
279 and targeted treatments. The development of such nanoscale products is vital because it will lead 
280 to early detection as well as a prompt localized treatment only to the affected body tissues such 
281 as cancer cells. The idea of a carrier to target, detect and treat a non-healthy cell is better known 
282 as Theranostics. This system combines detection agents used in diagnosis as well as the drugs 
283 used for treatment leading to an all-in-one, localized, diagnostic and treatment system. 
284 Nowadays researchers are studying nano-theranostic systems that use imaging nanoparticles able 
285 to use therapeutic systems [57].
286 Theranostic nanoparticles were also having the advantage over normal radiation as radiation may 
287 produce some damages to healthy tissue in contrast to the radio-sensitized nanoparticles that only 
288 affect the diseased cells while limiting the dose to healthy organs [58]. A very recent study 
289 conducted was using all in one Theranostic system nano-agent with ROS generation, PDT and 
290 CTD. These researchers have developed a Biocompatible copper ferrite nano-sphere (CFNs) that 
291 was used to intensify the ROS production by laser creating direct electron transfer and photo 
292 enhanced Fenton reaction in addition to increasing the photothermal conversion creating a 
293 synergistic action on the treatment. By using the oxygen generation properties while depleting 
294 the copper ferrite nano-spheres from glutathione they were able to come up with better 
295 photodynamic therapy and photodynamic therapy for cancer eradication in general [59].
296 Future Perspectives:
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297 The overall goal of adjuvant therapy is patient survival and should be based on toxicity, ease of 
298 administration, and cost since it is for longer duration generally for 6 months. Therefore, better 
299 strategies that provides not only improved adjuvants but also that allows self-administration with 
300 minimum side effects. The oral route offers significant advantages over other routes of 
301 administration like flexibility in the design of dosage form, ease of manufacturing with least 
302 sterility constraints, patient convenience, self-administration, cost-effectiveness. However, oral 
303 bioavailability of many anticancer drugs are low and highly variable, low solubility and low 
304 permeability, instability, and metabolism by intestinal and hepatic enzymes. Therefore as of now, 
305 only few drugs have reached the market. Many pharmaceutical approaches have been identified 
306 for colon drug delivery following oral administration such as prodrugs, covalent linkage of a 
307 drug with a carrier, pressure dependent systems, pH-sensitive systems, timed released systems, 
308 microbially triggered systems, bioadhesive systems, osmotic controlled drug delivery systems. 
309 Nanoparticle formulations such as nanoparticles, nanoemulsions, liposomes are also developed 
310 to deliver adequate amounts of the drug to the tumor-targeted cells especially the CSC's niches, 
311 have shown great therapeutic effectiveness against pump-mediated drug resistance as well as 
312 reducing the harmful effects on normal cells due to its selectivity. In this era of precision 
313 oncology as more specific and cost effective techniques for molecular profiling of colorectal 
314 tumors are evolving, more specific adjuvant therapies based on molecular subtypes of colorectal 
315 tumors will emerge. Advances in bioinformatics and availability of high-throughput gene 
316 expression and other functional genomics data sets such as Gene Expression Omnibus (GEO) 
317 database had led to identification of potential biomarkers for the management of CRC [60,61]. 
318 New therapeutic targets including PD-1/PD-L1 [62], NEK2 [63], COL1A1 [63], BCL9 [64], miR-
319 124 [65], 9p21 locus [66] and many others associated with progression and prognosis of 
320 colorectal cancers were identified by integrating protein-protein interactions (PPIs) network and 
321 gene expression data and co-expression analysis. In earlier study, combination of NEK2 siRNA 
322 and chemotherapeutic agent cisplatin showed improved antitumor activity in colorectal cancer 
323 suggesting the benefits of combined treatment using potential therapeutic targets with traditional 
324 chemotherapeutic agents [67]. In near future, combining these gene targets along with other 
325 therapies will be a viable approach for treatment of CRC. It is hoped that these innovations, 
326 particularly those in nanotechnology, will facilitate effective and safe oral chemotherapy at 
327 home, without introducing further cost for healthcare systems in near future. However, 
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328 adherence to oral therapy needs to address properly. Overall, authors believe that oral route is a 
329 promising approach especially for colorectal cancer.
Executive summary
 Overview on colorectal cancer (CRC)
• Colorectal Cancer ranks third in terms of deaths and incidents in both genders.
• Nowadays there are many treatment options available for CRC such as surgery, 
chemotherapy, radiotherapy and targeted therapies that differ depending on the stage of the 
cancer.
• Patients prefer oral non-invasive chemotherapy in comparison to IV chemotherapy.
• The site of action as well as mode of action of the chemotherapeutic and chemopreventive 
agents influence the rationale for colon-targeted oral drug delivery.
Non-invasive treatment approaches for colorectal cancer (CRC)
o New studies that are aiming to transfer chemotherapeutic agents to oral treatments to increase 
patient compliance such as the development of TAS-102 (Lonsurf), Capecitabine (Xeloda), 
oral irinotecan and Oxiplatin.
o Since CRC treatments are being limited due to cancer chemo- resistance scientists have 
started incorporating drugs in nanocarriers such as liposomes to fight resistance and solve 
drug delivery problems.
o Recent studies focus on using immunotherapy treatment for CRC as they function by 
overcoming or relieving tumour-induced immunosuppression, and enable immune-mediated 
tumour clearance. Regorafenib (Stivarga) is an example of such oral immunotherapy.
o A new technology that combines detection agents used in diagnosis as well as the drugs used 
for treatment leading to what’s known as an all-in-one, localized, diagnostic and treatment 
system. 
o In this era of precision oncology as more specific and cost effective techniques for molecular 
profiling of colorectal tumors are evolving, more specific adjuvant therapies based on 
molecular subtypes of colorectal tumors will emerge. It is hoped that these innovations, 
particularly those in nanotechnology, will facilitate effective and safe oral chemotherapy at 
home, without introducing further cost for healthcare systems.
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Stage Definition Treatment Options
Stage 0 Localized; didn’t grow beyond the colon inner lining. Polyps are removed during colonoscopy (also known as polypectomy)
Stage I Cancer grown deeper through the colon wall layers, however, it has not 
spread yet.
Removal of affected area through local excision (resection surgery)
Stage II Cancer grown outside the colon wall and possibly spread to nearby 
tissue but not yet spread through the lymph nodes. Further divided into 
3 types, IIA, IIB and IIC.
Resection surgery with or without adjuvant chemotherapy
Stage III Cancer spread to close by lymph nodes. Further divided into 3 types, 
IIIA, IIIB and IIIC.
Surgical resection with adjuvant  chemotherapy and other therapies if 
necessary, Radiation and/or chemotherapy
Stage IV Cancer spread all over 
 the body and reached the metastatic stage. Further divided into 2 types; 
IVA and IVB
Surgical resection of colon along with surgical removal of other affected 
parts of the body, chemotherapy Combinations of chemo and/or targeted 
therapies before or after surgery, Radiation therapy for symptomatic relief
Table 1:  Different stages of colorectal cancer and their treatment options [68]
































































Table 2: Oral chemotherapy Drugs used in Colorectral 
Cancer in the Market 
Chemotherapy Trade name Class
Capecitabine Xeloda® Antineoplastics, Antimetabolite
Regorafenib Stivarga® Receptor tyrosine kinase inhibitor
Trifluridine-tipiracil 
hydrochloride
Lonsurf® Trifluridine: thymidine-based nucleoside 
analogues. 
Tipiracil: thymidine phosphorylase 
inhibitors.
Tegafur/Uracil Uracel TM Dihydropyrimidine dehydrogenase 
inhibitory fluoropyrimidines

































































Figure 1: Currently Available Adjuvant Therapy for Colorectal Cancer 
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Figure 2: Main pathways through which drug act on colon cancer following oral administration. The first 
pathway (1) follow absorption of drugs into systemic circulation, while second pathway (2) allows local 
targeting to colon site 
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